Applicability of 99mTc-HL91, a putative hypoxic tracer, to detection of tumor hypoxia

Journal of Nuclear Medicine

Volumn 40, Issue 5, 1999, Pages 854-861

  Yutani, Kenji ^a   Kusuoka, Hideo ^a   Fukuchi, Kazuki ^a   Tatsumi, Mitsuaki ^a   Nishimura, Tsunehiko ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

14C deoxyglucose; 99mTc; Glucose transporter 1; HL91; Tumor hypoxia

Indexed keywords

CARBON 14; DEOXYGLUCOSE; GLUCOSE TRANSPORTER; NITROIMIDAZOLE DERIVATIVE; TRACER; UNCLASSIFIED DRUG; UPENAZIME; UPENAZIME TC 99M; CARBON; DIAGNOSTIC AGENT; OXIME; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M 4,9 DIAZA 3,3,10,10 TETRAMETHYLDODECAN 2,11 DIONE DIOXIME; TECHNETIUM TC 99M 4,9-DIAZA-3,3,10,10-TETRAMETHYLDODECAN-2,11-DIONE DIOXIME;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; DENSITOMETRY; FEMALE; HYPOXIA; IMMUNOHISTOCHEMISTRY; IMPLANTATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; RAT; TISSUE DISTRIBUTION; ANIMAL; CARCINOMA; EXPERIMENTAL NEOPLASM; METABOLISM; SCINTISCANNING; WISTAR RAT;

ANIMALS; CARBON RADIOISOTOPES; CARCINOMA 256, WALKER; DEOXYGLUCOSE; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MONOSACCHARIDE TRANSPORT PROTEINS; ORGANOTECHNETIUM COMPOUNDS; OXIMES; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 0032587878     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Gatenby RA, Coia LR, Richter MP, et al. Oxygen tension in human tumors: in vivo mapping using CT-guided probes. Radiology. 1985;156:211-214.
2. 2 tension measurements. Cancer Res. 1991;51:3316-3322.
3. Gatenby RA, Kessler HB, Rosenblum JS, et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship in outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 1988;14:831-838.
4. 2 histography as predictive assay in advanced cancer of the uterine cervix. In: Vaupel P, et al., eds. Oxygen transport to tissue XV. New York, NY: Plenum; 1994:445-450.
5. Vanderkooi JM, Erecinska M, Silver IA. Oxygen in mammalian tissue: methods of measurement and affinities of various reactions. Am J Physiol 1991;260:C1131-C1150.
6. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995;22:265-280.
7. 3H]fluoromisonidazole in ischemic myocardium. J Nucl Med. 1989;30:194-201.
8. Shelton ME, Dence C, Hwang D-R, Welch MJ, Bergmann SR. Myocardial kinetics of fluorine-18 misonidazole: a marker of hypoxic myocardium. J Nucl Med. 1989;30:351-358.
9. Martin GV, Cerqueira M, Caldwell JH, Rasey JS, Embree L, Krohn KA. Fluoromisonidazole: a metabolic marker of myocyte hypoxia. Circ Res. 1990;67: 240-244.
10. Shelton ME, Dence CS, Hwang D-R, Herrero P, Welch MJ, Bergmann SR. In vivo delineation of myocardial hypoxia during coronary occlusion using fluorine-18 fluoromisonidazole and positron emission tomography: a potential approach for identification of jeopardized myocardium. J Am Coll Cardiol. 1990;16:477-485.
11. Martin GV, Caldwell JH, Graham MM, et al. Noninvasive detection of hypoxic myocardium using fluorine-18-fluoromisonidazole and positron emission tomography. J Nucl Med. 1992;33:2202-2208.
12. Martin GV, Biskupiak JE, Caldwell JH, Rasey JS, Krohn KA. Characterization of iodovinylmisonidazole as a marker for myocardial hypoxia. J Nucl Med. 1993;34:918-924.
13. Chapman JD. Hypoxic sensitizers: implications for radiation therapy. N Engl J Med. 1979;301:1429-1432.
14. Rasey JS, Krohn KA, Grunbaum Z, Conroy PJ, Bauer K, Sutherland RM. Further characterization of 4-bromomisonidazole as a potential detector of hypoxic cells. Radiat Res. 1985;102:76-85.
15. 3H-misonidazole to solid human tumors as a measure of tumor hypoxia. Int J Radiat Oncol Biol Phys. 1986;12:1263-1267.
16. Rasey JS, Koh W-J, Grierson JR, Grunbaum Z, Krohn KA. Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys. 1989;17:985-991.
17. Koh W-J, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys. 1992;22:199-212.
18. Mannan RH, Somayaji VV, Lee J, Mercer JR, Chapman JD, Wiebe LI. Radioiodinated 1-(5-iodo-5-deoxy-β-D-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia. J Nucl Med. 1991;32:1764-1770.
19. 123I-iodoazomycin arabinoside: preliminary report of a clinical study. Br J Cancer. 1992;65:90-95.
20. Groshar D, McEwan AJB, Parliament MB, et al. Imaging tumor hypoxia and tumor perfusion. J Nucl Med. 1993;34:885-888.
21. Yang DJ, Wallace S, Cherif A, et al. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology. 1995;194: 795-800.
22. Rumsey WL, Cyr JE, Raju N, Narra RK. A novel [99m]technetium-labeled nitroheterocycle capable of identification of hypoxia in heart. Biochem Biophys Res Commun. 1993;193:1239-1246.
23. Kusuoka H, Hashimoto K, Fukuchi K, Nishimura T. Kinetics of a putative hypoxic tissue marker, technetium-99m-nitroimidazole (BMS181321), in normoxic, hypoxic, ischemic and stunned myocardium. J Nucl Med. 1994;35:1371-1376.
24. 99mTc-labeled nitroimidazole (BMS181321), after regional ischemia and reperfusion. Circulation. 1995;92:1246-1253.
25. Rumsey WL, Patel B, Linder KE. Effect of graded hypoxia on retention of technetium-99m-nitroheterocycle in perfused rat heart. J Nucl Med. 1995;36:632-636.
26. Shi CQ, Sinusas AJ, Dione DP, et al. Technetiutn-99m-nitroimidazole (BMS181321): a positive imaging agent for detecting myocardial ischemia. J Nucl Med. 1995;36:1078-1086.
27. Fukuchi K, Kusuoka H, Watanabe Y, Fujiwara T, Nishimura T. Ischemic and reperfused myocardium detected with technetium-99m-nitroimidazole. J Nucl Med. 1996;37:761-766.
28. Ballinger JR, Kee JWM, Rauth AM. In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia. J Nucl Med. 1996;37:1023-1031.
29. Archer CM, Edwards B, Kelly JD, King AC, Burke JF, Riley ALM. Technetium labeled agents for imaging tissue hypoxia in vivo. In: Nicolini M, Bandoli G, Mazzi U, eds. Proceedings of the Fourth International Symposium on Technetium in Chemistry and Nuclear Medicine. Padova, Italy: SGE Ditoriali; 1995:535-539.
30. 99mTc-HL91 effects of low flow and hypoxia on a new ischemia-avid myocardial imaging agent. Circulation. 1997;95:1892-1899.
31. Cook GJR, Houston S, Barrington SF, Fogelman I. Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG. J Nucl Med. 1998;39:99-103.
32. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between GLUT-1 expression and FDG uptake. J Nucl Med. 1996;37:1042-1047.
33. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med. 1995;36:1625-1632.
34. Loike JD, Cao L, Brett J, Ogawa S, Silverstein SC, Stern D. Hypoxia induces glucose transporter expression in endothelial cells. Am J Physiol. 1992;263:C326-C333.
35. Rigo P, Paulus P, Kaschten BJ, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med. 1996;23:1641-1674.